Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J 
Welcome,         Profile    Billing    Logout  
 4 Diseases   6 Trials   6 Trials   725 News 


«123456789»
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    [VIRTUAL] LONG-ACTING INJECTABLE ANTIPSYCHOTICS (LAIS): THE AUSTRALASIAN EXPERIENCE () -  Oct 14, 2021 - Abstract #WPAI2021WPA_I_350;    
    While narrating the Australasian experience, the focus remain on the wider implications of the issues involved. Future directions will be outlined, including the advent of 3-monthly paliperidone injection and the US FDA approval for the 6-monthly preparation..
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    Clinical, Observational data, Journal, Adverse events:  Fatal and life-threatening ADRs associated with paliperidone palmitate: an observational study in the French pharmacovigilance database. (Pubmed Central) -  Oct 10, 2021   
    It is hypothesized that cardiac arrests and sudden unexpected deaths following initiation of paliperidone palmitate treatment could be due to supratherapeutic drug concentrations. This paper proposes the need to monitor blood concentrations of paliperidone palmitate in future studies.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    Review, Journal:  Paliperidone 3-Month Injection for Treatment of Schizophrenia: A Narrative Review. (Pubmed Central) -  Oct 9, 2021   
    The results demonstrated that 50% of patients who were withdrawn from ORAL paliperidone, PP1M, or PP3M remained relapse-free for ~2, 6, and 13 months, respectively. Compared to PP1M, PP3M is just as safe and effective and has the added advantage of increased adherence related to a longer dose interval, decreasing the risk of relapse.
  • ||||||||||  Abilify Maintena (aripiprazole depot formulation) / Otsuka, Lundbeck, Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    Trial completion date, Trial primary completion date:  Substance Misuse To Psychosis for Stimulants (clinicaltrials.gov) -  Aug 18, 2021   
    P2/3,  N=240, Recruiting, 
    ClinicalTrials.gov identifier: NCT01157351. Trial completion date: Mar 2022 --> Dec 2022 | Trial primary completion date: Dec 2021 --> May 2022
  • ||||||||||  Abilify Maintena (aripiprazole depot formulation) / Otsuka, Lundbeck, Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Journal:  Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate. (Pubmed Central) -  Aug 6, 2021   
    The introduction of ALAI had a substantial impact on long-term clinical outcomes in this naturalistic cohort; more than half of patients continued treatment and had no admission during 2 years of follow up. There were no significant differences in hospitalisation rates between patients on ALAI and PP1M at 2 years.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Clinical, Journal:  Long-Acting Injectable Antipsychotic Use in Patients with Schizophrenia and Criminal Justice System Encounters. (Pubmed Central) -  Jun 1, 2021   
    The incidence of arrests was lower in the 6-month (27 vs 85 arrests), 1-year (46 vs 132 arrests) and 2-year (88 vs 196 arrests) periods post-index LAI medication than in the corresponding periods pre-index LAI medication among individuals with a history of prior arrest. Patients with schizophrenia or schizoaffective disorder who were initiated on a LAI antipsychotic medication, specifically PP1M, were less likely to have an encounter with the criminal justice system compared with a similar time period before the initiation of LAI treatment.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Clinical, PK/PD data, Journal:  Population Pharmacokinetics of Paliperidone Palmitate (Once-Monthly Formulation) in Japanese, Korean, and Taiwanese Patients With Schizophrenia. (Pubmed Central) -  May 29, 2021   
    The paliperidone pharmacokinetics after intramuscular administration of once-monthly paliperidone palmitate in Japanese patients were studied in 3 phase 1 studies and in 2 phase 3 studies performed in Japan, Korea, and Taiwan...Paliperidone pharmacokinetics were adequately predicted for Japanese studies using the historical Pop-PK model, confirming its robustness. Pharmacokinetics in Japanese, Korean, and Taiwanese patients with schizophrenia were comparable with rest-of-world population.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    Clinical, Journal:  Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate. (Pubmed Central) -  May 21, 2021   
    Pharmacokinetics in Japanese, Korean, and Taiwanese patients with schizophrenia were comparable with rest-of-world population. Reducing the frequency of antipsychotic medication administration in stable patients with schizophrenia by switching from PP1M to PP3M may reduce carer burden.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    [VIRTUAL] The Shortcomings in AOT in Adeqautely Treating Patients With Severe Mental Illness () -  May 2, 2021 - Abstract #APA2021APA_775;    
    with SMI including Schizophrenia and non-complaint with oral meds should be on LAI to prevent decompensation and ensure their treatment compliance and stability in the community. Additionally, the role of AOT should not only be to ensure pts.’ compliance with psychiatric appointments but also with psychiatric treatment including LAI if the need may be even if it has to be mandated by the court like the enrollment in AOT itself.
  • ||||||||||  [VIRTUAL] Have We Forgotten About Lithium Induced EPS? () -  May 2, 2021 - Abstract #APA2021APA_319;    
    Due to her psychosis and history of non-adherence, she was started on risperidone for bipolar I disorder, current episode manic with psychotic features, and transitioned to paliperidone long acting injectable (Invega Sustenna)...To target to her sustained manic symptoms, lithium carbonate extended-release was initiated...The patient’s parkinsonian symptoms persisted despite multiple doses of diphenhydramine, benztropine, lorazepam, and amantadine...Mood stabilizers and neuroleptics are often used in combination to treat acutely decompensated patients with affective disorders. Therefore, it is also important to appreciate that lithium alone can induce EPS, and when added to an antipsychotic, can precipitate EPS.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    [VIRTUAL] Adolescents and dual pathology. Assessment of treatment with paliperidona palmitato long-term injectables. (e-Poster Gallery) -  Apr 26, 2021 - Abstract #EPA2021EPA_1474;    
    Determine the consumption of toxins after treatment.  Methods Sample: Adolescents, 14-17 years old, with a diagnosis of Personality Limit T and cocaine consumption who start treatment with Paliperidone Palmitate LD IM (50-100mg / month) in monotherapy, with Diazepam 5mg if significant anxiety...A decrease in the consumption of toxins was observed in 65% of the cases.  Conclusions In our experience, the management of toxic consumption in adolescent population with severe impulsivity symptoms has great limitations due to the scarce resources available. The Palpitate of Paliperidone long-term treatment has been useful in the approach of serious registered cases, being associated with symptomatic improvement and decrease in consumption.
  • ||||||||||  Abilify Maintena (aripiprazole depot formulation) / Otsuka, Lundbeck, Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    [VIRTUAL] Assessment of hospitalizations in schizophrenia patients treated with Paliperidone 1-monthly (PP1M), Paliperidone 3-monthly (PP3M), Aripiprazole once-monthly (AOM) and other oral antipsychotics (OAP) in clinical practice. (e-Poster Gallery) -  Apr 26, 2021 - Abstract #EPA2021EPA_965;    
    However, limited real world evidence is available as to whether there are differences among the various formulations marketed.  Objectives This study aims to assess the impact on several prognosis variables of PP1M,PP3M,AOM and OAP drugs.  Methods All adults (≥18 years) with schizophrenia who were initiated on PP1M, PP3M, AOM, or OAP treatment (chlorpromazine,levomepromazine,fluphenazine,haloperidol,ziprasidone,zuclopenthixol,olanzapine,quetiapine,asenapine,amisulpride, risperidone,aripiprazole,paliperidone) between 2017 and 2018 were identified in IQVIA’s database(1.8M of inhabitants from 4 Spanish areas)...01) for PP3M (23%) than for PP1M (36.9%), OAP (43.5%),and AOM (46.2%). Persistence rates were higher for PP3M (91%) than for any other treatment (p<0.01).  Conclusions Our results outline that patients treated with PP3M experienced fewer relapses and decompensations compared to all other treatments analyzed, which might help improve the prognosis and quality of life of patients.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    [VIRTUAL] The Systematic Analysis of Psychiatric Outcomes in Patients Converted from 1-month to 3-month Paliperidone Palmitate Long-Acting Injections () -  Apr 4, 2021 - Abstract #CPNP2021CPNP_237;    
    Patients are considered non-adherent if a subsequent dose was administered within greater than four months since previous dose. Outcomes: We will report the number and percentages of subjects with worsened/improved adherence, hospitalizations, and efficacy in patients converted from PP1M to PP3M as a function of demographic characteristics, MHICM/ALF enrollment, dual anti-psychotic treatment, and indication for conversion to PP3M.
  • ||||||||||  risperidone / Generic mfg.
    [VIRTUAL] Evaluation of Atypical Long-Acting Injectable Antipsychotics for Substance-Induced Psychosis in a Veteran Population () -  Apr 4, 2021 - Abstract #CPNP2021CPNP_180;    
    Small randomized controlled trials and case studies demonstrate that antipsychotics are efficacious in treating inhalant-, methamphetamine-, and alcohol-induced psychosis...Although there is literature to support the use of LAIAs for SIPD, to our knowledge there are no studies comparing the atypical LAIAs risperidone intramuscular extended release suspension, aripiprazole monohydrate, and monthly paliperidone palmitate... In progress.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    [VIRTUAL] Treatment of Schizophrenic Patients with Once-Every-3- Months Paliperidone Palmitate Injectable () -  Mar 7, 2021 - Abstract #CINP2021CINP_176;    
    The psychiatric symptoms 0f the patients were adequately managed by medications. PP3m has the potential to improve drug adherence and lead to better prognoses as the patients only need 4 intramuscular doses per year.
  • ||||||||||  Abilify Maintena (aripiprazole depot formulation) / Otsuka, Lundbeck
    [VIRTUAL] Real-world Functional Outcomes in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone () -  Mar 7, 2021 - Abstract #CINP2021CINP_164;    
    Patients with recent-onset schizophrenia in this study’s sample showed considerable improvements in functional outcome, as assessed by the GAF, after at least 6 months treatment with AOM 400 or PP1M, with AOM 400 yielding significantly greater improvements vs. PP1M. Other measures assessing functionality/quality of life (PSP, PANSS, QLS) also suggested benefits of AOM 400 over PP1M in several items.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    [VIRTUAL] Seasonal Antipsychotic in Schizophrenia - Outcomes in Naturalistic Settings in Canada (SEASONS): Real-Life Results of the Switch from 1-Month Paliperidone to 3-Month Paliperidone Long Acting Injectable Formulation () -  Mar 1, 2021 - Abstract #SIRS2021SIRS_281;    
    In 2016, a 3-monthly LAI formulation of paliperidone palmitate (Invega Trinza®) was introduced as a new therapeutic tool for schizophrenia treatment...In regard to previous antipsychotic treatment, patients had been receiving Invega Sustenna® for 2.3 years on average and only initial Invega Trinza® mean dose differed between those who relapsed and those who did not (430mg vs 381mg, p = .013)...While adequate compliance to Invega Trinza® treatment was thoroughly documented in the present study, adherence to other pharmacological and non-pharmacological treatments, such as psychotherapy, was not. Although other components of this study are still ongoing, results available so far highlight the importance of considering population characteristics included in RCTs before generalizing findings to real-life clinical settings.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    [VIRTUAL] Seasonal Antipsychotic in Schizophrenia - Outcomes in Naturalistic Settings in Canada (SEASONS): Real-Life Results of the Switch from 1-Month Paliperidone to 3-Month Paliperidone Long Acting Injectable Formulation () -  Mar 1, 2021 - Abstract #SIRS2021SIRS_109;    
    In 2016, a 3-monthly LAI formulation of paliperidone palmitate (Invega Trinza®) was introduced as a new therapeutic tool for schizophrenia treatment...In regard to previous antipsychotic treatment, patients had been receiving Invega Sustenna® for 2.3 years on average and only initial Invega Trinza® mean dose differed between those who relapsed and those who did not (430mg vs 381mg, p = .013)...While adequate compliance to Invega Trinza® treatment was thoroughly documented in the present study, adherence to other pharmacological and non-pharmacological treatments, such as psychotherapy, was not. Although other components of this study are still ongoing, results available so far highlight the importance of considering population characteristics included in RCTs before generalizing findings to real-life clinical settings.